NZ610378A - Lipoyl compounds and their use for treating ischemic injury - Google Patents
Lipoyl compounds and their use for treating ischemic injuryInfo
- Publication number
- NZ610378A NZ610378A NZ610378A NZ61037811A NZ610378A NZ 610378 A NZ610378 A NZ 610378A NZ 610378 A NZ610378 A NZ 610378A NZ 61037811 A NZ61037811 A NZ 61037811A NZ 610378 A NZ610378 A NZ 610378A
- Authority
- NZ
- New Zealand
- Prior art keywords
- lipoyl
- compounds
- ischemic injury
- treating ischemic
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41524010P | 2010-11-18 | 2010-11-18 | |
| US41524110P | 2010-11-18 | 2010-11-18 | |
| US201161478310P | 2011-04-22 | 2011-04-22 | |
| US201161500974P | 2011-06-24 | 2011-06-24 | |
| PCT/US2011/060259 WO2012067947A1 (en) | 2010-11-18 | 2011-11-10 | Lipoyl compounds and their use for treating ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ610378A true NZ610378A (en) | 2015-05-29 |
Family
ID=45217651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ610378A NZ610378A (en) | 2010-11-18 | 2011-11-10 | Lipoyl compounds and their use for treating ischemic injury |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8815937B2 (enExample) |
| EP (1) | EP2640423B1 (enExample) |
| JP (3) | JP2014502264A (enExample) |
| KR (1) | KR20140020840A (enExample) |
| CN (1) | CN103561770B (enExample) |
| AU (1) | AU2011329215C1 (enExample) |
| BR (1) | BR112013012057B1 (enExample) |
| CA (1) | CA2817362C (enExample) |
| DK (1) | DK2640423T3 (enExample) |
| ES (1) | ES2640474T3 (enExample) |
| IL (1) | IL226258A (enExample) |
| MX (1) | MX344933B (enExample) |
| NZ (1) | NZ610378A (enExample) |
| SG (1) | SG190794A1 (enExample) |
| WO (1) | WO2012067947A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| ES2640474T3 (es) | 2010-11-18 | 2017-11-03 | Ischemix Llc | Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica |
| ITFI20120170A1 (it) * | 2012-08-28 | 2014-03-01 | Consorzio Interuniversitario Nazion Ale Per La Sci | Nuovi composti ad azione anti-allodinica ed anti-iperalgesica. |
| WO2015128697A1 (en) | 2014-02-27 | 2015-09-03 | Consorzio Interuniversitario Nazionale Per La Scienza E Tecnologia Dei Materiali | Novel compounds having anti-allodynic and antihyperalgesic activity |
| WO2015174948A1 (en) | 2014-05-14 | 2015-11-19 | Ischemix, LLC | Formulations comprising lipoyl compounds |
| EP4018997A1 (en) * | 2016-03-14 | 2022-06-29 | NeoStrata Company, Inc. | N-lipoic -amino acid or peptide, derivatives and their uses |
| RU2657820C1 (ru) * | 2017-03-13 | 2018-06-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | 4-(4-Ацетоксибензоиламино)бутаноилглицин, обладающий церебропротекторным действием при ишемии головного мозга |
| EP3615023B1 (en) | 2017-04-25 | 2023-06-21 | Ischemix LLC | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury |
| US20240124520A1 (en) * | 2019-10-16 | 2024-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | N-acylated histidine dipeptides as anticancer agents |
| US11306076B2 (en) * | 2020-05-11 | 2022-04-19 | Xi'an Taikomed Pharmaceutical Technology Co., Ltd. | Silibinin lipoic acid ester with hepatoprotective activity and a method of preparing the same |
| CN116199666B (zh) * | 2023-03-07 | 2025-02-28 | 中国药科大学 | 两亲性化合物及其药物组合物 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875207A (en) | 1967-01-25 | 1975-04-01 | Ciba Geigy Corp | Process for the temporary protection of amino groups in peptide syntheses |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| CA1219824A (en) | 1981-04-17 | 1987-03-31 | David C. Ward | Modified nucleotides and methods of preparing and using same |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5288706A (en) | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| FR2653334B1 (fr) | 1989-10-19 | 1991-12-20 | Erphar Ste Civile | Preparation cosmetique de bronzage. |
| PT95826B (pt) | 1989-11-09 | 1997-11-28 | Asta Medica Ag | Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico |
| DE4000397A1 (de) | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
| JPH07505900A (ja) | 1992-04-24 | 1995-06-29 | バイオコンパテイブルズ・リミテツド | 金属皮膜 |
| WO1997000889A1 (en) | 1995-06-21 | 1997-01-09 | Asahi Kasei Kogyo Kabushiki Kaisha | Peptides binding to low-density lipoproteins |
| JPH0990542A (ja) | 1995-09-28 | 1997-04-04 | Konica Corp | ハロゲン化銀写真感光材料 |
| FR2741075B1 (fr) | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant |
| WO1998010090A1 (en) | 1996-09-06 | 1998-03-12 | St. Elizabeth's Medical Center Of Boston, Inc. | Gata-6 transcription factor: compositions and methods |
| JPH11269170A (ja) * | 1997-04-02 | 1999-10-05 | Sankyo Co Ltd | ジチオラン誘導体 |
| IL123887A0 (en) | 1997-04-02 | 1998-10-30 | Sankyo Co | Dithiolan derivatives their use and pharmaceutical compositions containing the same |
| JPH117099A (ja) | 1997-06-13 | 1999-01-12 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| US6090842A (en) | 1998-03-10 | 2000-07-18 | The Regents Of The University Of California | Lipoic acid analogs |
| JP2000169371A (ja) * | 1998-10-02 | 2000-06-20 | Sankyo Co Ltd | ジチオラン誘導体を含有する医薬 |
| JP2002535247A (ja) | 1998-11-26 | 2002-10-22 | ペンタファルム アクチェンゲゼルシャフト | 輸送系複合体 |
| AU6462500A (en) | 1999-07-29 | 2001-02-19 | Patrick T. Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| EP2368898B1 (en) | 1999-11-18 | 2014-10-01 | Ischemix, Inc | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| JP2002189271A (ja) | 2000-12-21 | 2002-07-05 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその処理方法 |
| DE60234164D1 (de) | 2001-03-19 | 2009-12-10 | Senju Pharma Co | Neues a-liponsäurederivat und dessen verwendung |
| EP1521735A2 (en) | 2001-05-25 | 2005-04-13 | Ceremedix, Inc | Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| JP4259813B2 (ja) * | 2001-05-29 | 2009-04-30 | 千寿製薬株式会社 | α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤 |
| DE10163836A1 (de) | 2001-12-22 | 2003-07-10 | Friz Biochem Gmbh | Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren |
| JP4272068B2 (ja) | 2001-12-26 | 2009-06-03 | 日本曹達株式会社 | 自己組織化単分子膜を形成する電子受容性化合物 |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| WO2003072052A2 (en) | 2002-02-22 | 2003-09-04 | Albany College Of Pharmacy | Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease |
| JP2003286168A (ja) | 2002-03-28 | 2003-10-07 | Senju Pharmaceut Co Ltd | α−リポイルアミノ酸を含有する皮膚外用剤 |
| JP4376540B2 (ja) | 2002-05-31 | 2009-12-02 | アイバイツ株式会社 | 金属表面修飾剤および新規含硫黄化合物 |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| US20040204340A1 (en) | 2003-04-11 | 2004-10-14 | Guilford Pharmaceuticals, Inc. | Polyprolyl inhibitors of cyclophilin |
| WO2005063732A1 (en) | 2003-12-23 | 2005-07-14 | Microbia, Inc. | Compounds and methods for the treatment of asthma |
| CA2556406C (en) | 2004-02-18 | 2013-04-02 | Japan Science And Technology Agency | Sugar chain ligand composite and method of analyzing protein with the ligand composite |
| JP2006022066A (ja) * | 2004-07-09 | 2006-01-26 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| WO2006101910A2 (en) | 2005-03-16 | 2006-09-28 | Ischemix, Inc. | Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems |
| WO2006101909A2 (en) | 2005-03-16 | 2006-09-28 | Ischemix, Inc. | Combination therapy for treating or preventing diseases |
| JP2008174453A (ja) | 2005-04-28 | 2008-07-31 | Iwaki Kk | 頭皮脱毛治療剤 |
| EP1957093B1 (en) | 2005-08-29 | 2017-04-12 | SHASHOUA, Victor E. | Neuroprotective and neurorestorative methods and compositions |
| JP4951226B2 (ja) | 2005-09-08 | 2012-06-13 | 立山化成株式会社 | α−リポ酸アルカリ塩の製法 |
| WO2007030581A2 (en) | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| DE602006013787D1 (de) | 2006-03-28 | 2010-06-02 | Epitech Group Srl | Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden |
| US20110212954A1 (en) * | 2008-11-07 | 2011-09-01 | Mario Brufani | Alpha-lipoic acid derivatives and their use in drug preparation |
| US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| EP3069612A3 (en) * | 2009-06-15 | 2016-10-19 | Encore Health, LLC | Dithiol compounds, derivatives, and uses therefor |
| ES2579173T3 (es) * | 2009-06-15 | 2016-08-05 | Encore Health, Llc | Ésteres de colina para tratar presbicia y cataratas |
| IT1397154B1 (it) | 2010-01-04 | 2013-01-04 | Ghelardini | Composti ad efficacia sia analgesica che antiperalgesica. |
| ES2640474T3 (es) | 2010-11-18 | 2017-11-03 | Ischemix Llc | Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica |
| US20150329519A1 (en) | 2014-05-14 | 2015-11-19 | Ischemix, LLC | Formulations Comprising Lipoyl Compounds |
-
2011
- 2011-11-10 ES ES11793558.5T patent/ES2640474T3/es active Active
- 2011-11-10 JP JP2013539912A patent/JP2014502264A/ja active Pending
- 2011-11-10 KR KR1020137015640A patent/KR20140020840A/ko not_active Ceased
- 2011-11-10 CN CN201180065214.1A patent/CN103561770B/zh not_active Expired - Fee Related
- 2011-11-10 AU AU2011329215A patent/AU2011329215C1/en not_active Ceased
- 2011-11-10 DK DK11793558.5T patent/DK2640423T3/en active
- 2011-11-10 MX MX2013005508A patent/MX344933B/es active IP Right Grant
- 2011-11-10 NZ NZ610378A patent/NZ610378A/en not_active IP Right Cessation
- 2011-11-10 WO PCT/US2011/060259 patent/WO2012067947A1/en not_active Ceased
- 2011-11-10 BR BR112013012057-6A patent/BR112013012057B1/pt not_active IP Right Cessation
- 2011-11-10 CA CA2817362A patent/CA2817362C/en active Active
- 2011-11-10 US US13/885,289 patent/US8815937B2/en active Active
- 2011-11-10 SG SG2013036546A patent/SG190794A1/en unknown
- 2011-11-10 EP EP11793558.5A patent/EP2640423B1/en active Active
-
2013
- 2013-05-09 IL IL226258A patent/IL226258A/en active IP Right Grant
-
2014
- 2014-08-11 US US14/456,646 patent/US9359325B2/en active Active
-
2015
- 2015-11-27 JP JP2015232258A patent/JP6280094B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-02 JP JP2017213078A patent/JP2018016652A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2640474T3 (es) | 2017-11-03 |
| KR20140020840A (ko) | 2014-02-19 |
| AU2011329215A1 (en) | 2013-05-30 |
| IL226258A0 (en) | 2013-07-31 |
| CN103561770B (zh) | 2016-11-09 |
| AU2011329215C1 (en) | 2016-08-11 |
| IL226258A (en) | 2017-02-28 |
| DK2640423T3 (en) | 2017-10-02 |
| CA2817362A1 (en) | 2012-05-24 |
| JP6280094B2 (ja) | 2018-02-14 |
| EP2640423B1 (en) | 2017-07-26 |
| JP2016033157A (ja) | 2016-03-10 |
| AU2011329215B2 (en) | 2016-04-28 |
| WO2012067947A1 (en) | 2012-05-24 |
| US20150065564A1 (en) | 2015-03-05 |
| SG190794A1 (en) | 2013-07-31 |
| CA2817362C (en) | 2018-10-23 |
| US20130237483A1 (en) | 2013-09-12 |
| US9359325B2 (en) | 2016-06-07 |
| JP2018016652A (ja) | 2018-02-01 |
| BR112013012057A2 (pt) | 2020-08-04 |
| MX344933B (es) | 2017-01-11 |
| JP2014502264A (ja) | 2014-01-30 |
| EP2640423A1 (en) | 2013-09-25 |
| MX2013005508A (es) | 2013-07-17 |
| BR112013012057B1 (pt) | 2021-11-09 |
| US8815937B2 (en) | 2014-08-26 |
| CN103561770A (zh) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY155517A (en) | Heterocyclic derivatives | |
| MX344521B (es) | Aminas heterociclicas y sus usos. | |
| NZ597517A (en) | 5-fluoropyrimidinone derivatives | |
| MX336381B (es) | Boronatos como inhibidores de arginasa. | |
| TN2015000121A1 (en) | Gdf-8 inhibitors | |
| IN2012DN06602A (enExample) | ||
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MY162535A (en) | Inhibitors of arginase and their therapeutic applications | |
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| WO2010093849A3 (en) | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| SG178952A1 (en) | Chemical compounds | |
| UA102858C2 (ru) | Производные пиридино-пиридинонов, способ их получения и применения в терапии | |
| WO2011101069A3 (en) | 1, 8 -naphthyridines as kinase inhibitors | |
| MX2012006805A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. | |
| MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
| NZ597570A (en) | N1-acyl-5-fluoropyrimidinone derivatives | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| MX2015007053A (es) | Compuestos dimericos. | |
| WO2011047055A3 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX344933B (es) | Compuestos de lipoílo y su uso para tratar lesión isquémica. | |
| PH12012501265A1 (en) | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | |
| MX2010009837A (es) | Tiazolil-dihidro-indazoles. | |
| MX2010009999A (es) | Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2016 BY COMPUTER PACKAGES INC Effective date: 20151020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2017 BY COMPUTER PACKAGES INC Effective date: 20161018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2018 BY COMPUTER PACKAGES INC Effective date: 20171018 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2019 BY CPA GLOBAL Effective date: 20181011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2020 BY CPA GLOBAL Effective date: 20191024 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2021 BY CPA GLOBAL Effective date: 20201030 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2022 BY CPA GLOBAL Effective date: 20211022 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2023 BY CPA GLOBAL Effective date: 20221020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 NOV 2024 BY CPA GLOBAL Effective date: 20231019 |
|
| LAPS | Patent lapsed |